Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

Analysts at GlobalData have predicted that, fuelled by new indications, the two drugs could make peak combined sales of $32 billion by 2020, with Skyrizi accounting for around $20 billion of that ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...